Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on November 15, 2018. The report addresses a specific corporate event regarding the company's listing status on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and does not contain financial statement data.
Material Changes
On November 15, 2018, the Nasdaq Hearings Panel granted Trovagene, Inc.'s request for continued listing on The Nasdaq Capital Market. This decision is subject to the company's compliance with certain conditions.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future performance, or a discussion of general business risks. The primary contingency noted is the requirement to comply with specific conditions set by the Nasdaq Hearings Panel to maintain the listing.
Investor Verification Checklist
- Verify the specific conditions imposed by the Nasdaq Hearings Panel for continued listing.
- Review the attached press release (Exhibit 99.1) for details on the compliance timeline.
- Confirm the company's current financial status in subsequent filings (e.g., 10-Q or 10-K) as this 8-K contains no financial data.
- Note the leadership change indicated by the signature of Thomas Adams as Interim Chief Executive Officer.